| Mismatched' Prostate Cancer Treatment Prevalent
More than a third of men with early prostate cancer who participated in a study analyzing treatment choice received therapies that might not be appropriate, based on pre-existing problems with urinary, bowel or sexual function. The prevalence of these treatment "mismatches" could reflect patient' unwillingness to discuss such problems with their physicians. The study will appear in the January 1, 2008 issue of the journal Cancer and is being released online."Prostate cancer patients experience the same fears and hard decisions as all cancer patients do, but prostate cancer treatment directly affects very personal things that most people aren't comfortable talking about - urinary, bowel and sexual function," says James Talcott, MD, SM, of the Center for Outcomes Research at Massachusetts General Hospital (MGH) Cancer Center, who led the study.
Post-Prostatectomy Rehabilitation Improves Men's Natural Sexual ...
This year doctors will diagnose nearly 219,000 men with prostate cancer. Many will undergo radical prostatectomy surgery. While radical prostatectomy provides an excellent cure, impotence (erectile dysfunction) is a common side effect. However early, postoperative penile rehabilitation can speed prostatectomy patients' healing, achieve natural erectile function and improve their quality of life.Studies show that even 24 months after prostate cancer treatment sexual dysfunction was the most important quality of life issue. "Increasingly doctors are finding quality of life issues important in the overall treatment of any disease, including erectile dysfunction," said Dr. Skip Freedman, executive medical director for AllMed Healthcare Management.Treating erectile dysfunction has changed over the last several years, and can offer men a confusing number of treatment choices.
Prostate Cancer Treatment Centre Receives Funding for Clinical Trials
TORONTO, Nov. 14 /PRNewswire/ -- A Canadian study on High Intensity Focused Ultrasound therapy with the Sonablate(R) 500 - a Health Canada approved treatment for localized prostate cancer - is underway at Can-Am HIFU. Through funding from AstraZeneca Canada Inc, Can-Am HIFU, a prostate cancer treatment centre, will conduct an REB/Health Canada approved clinical trial. The objective of the study is to supplement current research findings on safety and efficacy of HIFU therapy in the treatment of localized prostate cancer. The trial will measure both the biochemical (PSA) cure rates and the Biopsy-proven cure rates at one year. "AstraZeneca is committed to promoting excellence in Canadian health science research and to supporting the growth of Canada's scientific community," says Marc Zarenda, Scientific Director - Oncology at AstraZeneca Canada Inc.
|
